"I believe that COMPASS Pathways is working to solve a truly significant health problem that impacts not only the individual but their entire family. I am excited to be a part of this mission."

Stephen Schultz

Senior Vice President, Investor Relations

Responsible for managing communications to and the relationship between COMPASS Pathways and the investment community, including investors, analysts and financial markets. The primary objective of the IR role is to assist the investment community in making informed decisions regarding an equity investment in COMPASS Pathways.

Steve has over 25 years of experience in investor relations, financial communications and media relations. Prior to joining COMPASS, Steve was the Vice President of Investor Relations at GW Pharmaceuticals, the world leader in developing cannabinoid-based therapeutics and the first company to receive FDA approval of a cannabis plant-derived medicine. At GW, Steve oversaw the IR and financial communications from its Nasdaq IPO in May 2013. Prior to GW, Steve oversaw the IR and corporate communications for Amarin Corporation, a company that develops and markets a prescription omega-3 fatty acid medicine for the treatment of cardiovascular disease. Prior to Amarin, Steve was the Executive Director of the Jackson Hole Center for the Arts, in Jackson, Wyoming.

"I believe that COMPASS Pathways is working to solve a truly significant health problem that impacts not only the individual but their entire family. I am excited to be a part of this mission."